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O13. VALIDATION OF JADAS IN ALL SUBTYPES
OF JUVENILE IDIOPATHIC ARTHRITIS IN A CLINICAL
SETTING
Flora McErlane1,2, Michael W. Beresford1,3, Eileen M. Baildam3,
Wendy Thomson2, Kimme Hyrich2, Alice Chieng7, Joyce Davidson5,
Helen E. Foster4, Janet Gardner-Medwin5, Mark Lunt2 and
Lucy Wedderburn6
1Institute of Child Health, University of Liverpool, Liverpool,
United Kingdom; 2School of Translational Medicine, University of
Manchester, Manchester, United Kingdom; 3Paediatric
Rheumatology, Alder Hey Children’s Hospital, Liverpool, United
Kingdom; 4Rheumatology, Newcastle Medical School, Newcastle
upon Tyne, United Kingdom; 5Rheumatology, Royal Hospital for Sick
Children, Glasgow, United Kingdom; 6Rheumatology Unit, Institute of
Child Health, London, United Kingdom; 7Rheumatology, Royal
Manchester Children’s Hospital, Manchester, United Kingdom
Background: Juvenile Arthritis Disease Activity Score (JADAS) is a
4 variable composite disease activity (DA) score for JIA (including
active 10, 27 or 71 joint count (AJC), physician global (PGA), parent/
child global (PGE) and ESR). The validity of JADAS for all ILAR
subtypes in the routine clinical setting is unknown. We investigated the
construct validity of JADAS in the clinical setting in all subtypes of JIA
through application to a prospective inception cohort of UK children
presenting with new onset inflammatory arthritis.
Methods: JADAS 10, 27 and 71 were determined for all children in
the Childhood Arthritis Prospective Study (CAPS) with complete data
available at baseline. Correlation of JADAS 10, 27 and 71 with single
DA markers was determined for all subtypes. All correlations were
calculated using Spearman’s rank statistic.
Results: 262/1238 visits had sufficient data for calculation of JADAS
(1028 (83%) AJC, 744 (60%) PGA, 843 (68%) PGE and 459 (37%)
ESR). Median age at disease onset was 6.0 years (IQR 2.6-10.4) and
64% were female. Correlation between JADAS 10, 27 and 71
approached 1 for all subtypes. Median JADAS 71 was 5.3 (IQR 2.2-
10.1) with a significant difference between median JADAS scores
between subtypes (p< 0.01). Correlation of JADAS 71 with each single
marker of DA was moderate to high in the total cohort (see Table 1).
Overall, correlation with AJC, PGA and PGE was moderate to high and
correlation with ESR, limited JC, parental pain and CHAQ was low to
moderate in the individual subtypes. Correlation coefficients in the
extended oligoarticular, rheumatoid factor negative and enthesitis
related subtypes were interpreted with caution in view of low numbers.
Conclusions: This study adds to the body of evidence supporting the
construct validity of JADAS. JADAS correlates with other measures of
DA in all ILAR subtypes in the routine clinical setting. Given the high
frequency of missing ESR data, it would be useful to assess the validity
of JADAS without inclusion of the ESR.
Disclosure statement: All authors have declared no conflicts of
interest.
O14. HAS ORTHOPAEDIC INTERVENTION FOR
RHEUMATOID ARTHRITIS CHANGED IN LINE WITH
COMBINATION AND ANTI-TNF THERAPIES? AN EVALUATION
OF JOINT SURGERY RATES AND PROGNOSTIC FACTORS IN
TWO UK INCEPTION COHORTS (1986–2011)
Elena Nikiphorou1, Lewis Carpenter2, Patrick Kiely3, David Walsh4,
Josh Dixey5 and Adam Young1
1Rheumatology, ERAS/ERAN, St Albans, United Kingdom; 2Centre
for Lifespan & Chronic Illness Research, University of Hertfordshire,
Hatfield, United Kingdom; 3Rheumatology, St George’s Healthcare
NHS Trust, London, United Kingdom; 4Academic Rheumatology,
Arthritis Research UK Pain Centre, University of Nottingham,
Nottingham, United Kingdom; 5Rheumatology, New Cross Hospital,
Wolverhampton, United Kingdom
Background: Orthopaedic surgery in RA is considered a surrogate
marker for joint destruction. It has been postulated that the need for
orthopaedic surgery would be reduced with greater use of more
intense therapies for RA. We were able to examine this proposal in two
UK multicentre inception cohorts conducted between 1986 & 2011.
Methods: The Early RA Study (ERAS) recruited from 1986-1999
(n¼ 1465), the Early RA Network (ERAN) from 2002 (n¼ 1236).
Symptom onset to baseline was median 6 months in both and time
to 1st DMARD was median 2 & 1 month respectively. Standardized
clinical, laboratory and x-ray measures were performed yearly in both
cohorts. Disease-modifying, steroid and biologic therapies reflected
conventional practice and guidelines of the time frames examined.
Source data of all orthopaedic interventions included clinical datasets
(patient report and medical records from 1986), which were validated
with Hospital Episode Statistics (HES from 1997) and the National
Joint Registry (NJR from 2002). Length of follow up was based on the
National Death Registry.
Results: In ERAS 558 patients (38%) had 1287 orthopaedic
procedures over a maximum of 25 years follow up. 18.5% had major
(e.g. total joint replacements), 16% had intermediate (e.g. wrist
synovectomy, forefoot arthroplasty), and 17% minor (e.g. carpal
tunnel release). In ERAN (max 9 years follow up) 216 patients
(17.5%) had 326 procedures, 7% major, 3.4% intermediate, 9%
minor. Graphic displays will show that secular declines in combined
major/intermediate surgical rates were seen from 1987-2011 (18 to 16
per 1000 patients/year), coinciding with use of more intensive
combination and biologic therapies. Declines were mainly in inter-
mediate type surgery of wrist, hands and feet (8 to 6 per 1000 patients/
year) and not in total joint replacements (mainly hip & knee). Risk
factors were also different for the two surgical groups. In univariate
analysis, women had increased risk for intermediate surgery only
(odds ratio 3.2, CI 2.21-4.7). Baseline and 1year DAS, HAQ, ESR,
Haemoglobin(HB) and erosions all predicted 5 & 10 year major and
intermediate surgery (ORs all significant around 1.5-2). Low HB
predicted a subgroup who had multiple joint surgery by 5 & 10years
(OR 2.6, CI 1.5-4.4 and OR 3.0, CI 2.1-4.4 respectively). In Cox
regression, sex, onset age and erosions predicted intermediate
surgery, and sex, onset age and HB predicted major surgery.
Conclusions: Orthopaedic surgery is an important and common
outcome in RA by 10 years, not often reported and difficult to predict.
Only hand/foot surgery rates showed a consistent decline from 1986-
2011, suggesting a different pathology or response to therapy between
large and small joint destructive processes. HB does not normally
TABLE 1 Spearman’s correlation between JADAS 71 and single markers DA by ILAR subtype
ILAR Subtype Systemic
onset JIA
Persistent
oligo JIA
Extended
oligo JIA
Rheumatoid
factor
neg JIA
Rheumatoid
factor
pos JIA
Enthesitis
related
JIA
Psoriatic
JIA
Undifferentiated
JIA
Unknown
subtype
Total
cohort
Number of children 23 111 12 57 7 9 19 7 17 262
AJC 0.54 0.67 0.53 0.75 0.53 0.34 0.59 0.81 0.37 0.59
PGA 0.63 0.69 0.25 0.73 0.14 0.05 0.50 0.83 0.56 0.64
PGE 0.51 0.68 0.83 0.61 0.41 0.69 0.71 0.9 0.48 0.61
ESR 0.28 0.31 0.35 0.4 0.6 0.85 0.43 0.7 0.5 0.53
Limited 71 JC 0.29 0.51 0.23 0.37 0.14 -0.12 0.4 0.81 0.45 0.41
Parental pain 0.23 0.62 0.03 0.57 0.41 0.69 0.7 0.79 0.42 0.53
Childhood health
assessment
questionnaire
0.25 0.57 -0.07 0.36 -0.47 0.84 0.37 0.8 0.66 0.47
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perform well as a predictor of outcome in RA, but did for orthopaedic
intervention.
Disclosure statement: All authors have declared no conflicts of
interest.
O15. PREDICTING RESPONSES TO ANTI-TNFa THERAPY
IN PATIENTS WITH RHEUMATOID ARTHRITIS USING
METABOLOMIC ANALYSIS OF URINE
Sabrina R. Kapoor1,2, Andrew Filer1,3, Martin Fitzpatrick1,
Benjamin A. Fisher5, Peter C. Taylor4, Christopher Buckley1,2,
Iain McInnes6, Karim Raza1,2 and Stephen P. Young1
1Rheumatology Research Group, University of Birmingham,
Birmingham, United Kingdom; 2Rheumatology, University of
Birmingham and Sandwell & West Birmingham Hospitals NHS Trust,
Birmingham, United Kingdom; 3Rheumatology, University Hospitals
Birmingham NHS Foundation Trust, Birmingham, United Kingdom;
4Kennedy Institute of Rheumatology, University of Oxford, Oxford,
United Kingdom; 5Rheumatology, Imperial College, London,
United Kingdom; 6Institute of Infection, Immunity and Inflammation,
University of Glasgow, Glasgow, United Kingdom
Background: Anti-TNFa therapies are highly effective in the treatment
of rheumatoid arthritis (RA) but a significant proportion of patients have
an inadequate response. Given the important role of TNFa in regulating
systemic and localized metabolism, we sought to determine if the
metabolic profile of patients prior to therapy could be used to predict
responses to anti-TNFa agents.
Methods: Urine was collected from 16 patients with RA before and
during therapy with infliximab or etanercept as part of a multicentre
study. All patients were female and the mean age was 51.5. 14
patients were positive for rheumatoid factor and 14 for the anti-CCP
antibody. All patients had a DAS28>4 at baseline. Urine metabolic
profiles were assessed using NMR spectroscopy. The relationship
between metabolic profiles and clinical outcomes was assessed (using
partial least square discriminant analysis (PLSDA), Galgo and PLS-R
analysis) and relevant metabolites were identified (using metabolite
databases and Chenomix).
Results: Baseline urine metabolic profiles were able to discriminate
between RA patients who did (7 patients) or did not (9 patients) have a
good response to anti-TNFa therapy according to EULAR criteria with
a sensitivity of 85.9% and specificity of 85.7% with several metabolites
(in particular citrate, creatinine and cresol) contributing. There was a
significant correlation between baseline metabolic profiles in the urine
samples and the extent of change in DAS 28 (PLS-R analysis p¼0.04).
In patients with RA who responded to TNFa antagonists, a good
response to therapy was associated with changes in the following
urinary metabolites: erythritol, phenylacetic acid, cresol, propionic
acid, methylamine, citrate, hippuric acid and creatinine. Urine samples
were also available for 20 patients with psoriatic arthritis (PsA). Similar
metabolites were identified in the urine samples of the patients with
PsA that responded to TNFa antagonists. We were unable to study the
ability of baseline urinary metabolite profiles to predict response in PsA
as all but one of the PsA patients responded according to predefined
criteria.
Conclusions: There are clear differences in the metabolic profiles
of baseline urine samples of RA patients who go on to respond well
to anti-TNFa therapy. This may be relevant in the development of
clinically useful predictive strategies.
Disclosure statement: C.B, B.F, I.M., P.T.: Merck provided funding
for the clinical study (but not for the metabolomic analysis reported
here). All other authors have declared no conflicts of interest.
O16. DOUBLE-BLIND STUDY OF TOCILIZUMABþ
METHOTREXATE VERSUS TOCILIZUMABþPLACEBO IN
PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS DESPITE
PRIOR METHOTREXATE: PROGRESSION OF STRUCTURAL
DAMAGE, QUALITY OF LIFE AND PHYSICAL FUNCTION AT
24 WEEKS
Maxime Dougados1, Karsten Kissel2, Howard Amital3,
Philip Conaghan4, Emilio Martin-Mola5, Evgeny Nasonov6,
Georg Schett7, Orrin Troum8, Tiina Veldi9, Corrado Bernasconi2 and
Tom Huizinga10
1Rheumatology, Paris-Descartes University, Cochin Hospital, Paris,
France; 2Roche, F. Hoffmann-La Roche Ltd, Basel, Switzerland;
3Rheumatology, Sheba Medical Center, Tel-Hashomer, Israel;
4NIHR-Leeds Biomedical Research Unit, University of Leeds, Leeds,
United Kingdom; 5Rheumatology, Hospital Universitario La Paz,
Madrid, Spain; 6Rheumatology, Institute of Rheumatology, Moscow,
Russian Federation; 7Department of Internal Medicine, Institute for
Clinical Immunology, University of Erlangen-Nuremberg, Erlangen,
Germany; 8Rheumatology, Keck School of Medicine, University
of Southern California, Santa Monica, California, United States of
America; 9Rheumatology, East-Tallinn Central Hospital, Tallinn,
Estonia; 10Rheumatology, Leiden University Medical Center, Leiden,
Netherlands
Background: Tocilizumab(TCZ) monotherapy is superior to metho-
trexate (MTX) in achieving clinical reduction of disease activity in
rheumatoid arthritis (RA). This analysis of data from phase 3b ACT-
RAY assesses outcomes in terms of progression of structural damage,
quality of life(QoL), & physical function.
Methods: In ACT-RAY, patients(pts)on MTX were randomized to
continue MTX with addition of TCZ 8 mg/kg every 4 wks or placebo
(PBO)þTCZ. The primary endpoint was Disease Activity Score in 28
joints(DAS28) remission rate[RR] at 24 wks. Radiographs of the hand &
feet were taken at baseline (BL) & wk24 & were scored by independent
readers blinded to treatment allocation, clinical response, & sequence
of X-rays. QoL was assessed by HAQ-DI & RAQoL.
Results: Of 556 pts randomized, 92%(n¼512;TCZþMTX¼ 260;
TCZþPBO¼ 252) completed 24 wks. Mean baseline characteristics
were similar for both gps (female, 80.3%;age, 53.3yrs; RA duration,
8.2 yrs; DAS28,6.35)except for radiographic scores (Table). DAS28
RR was 40.4% & 34.8% in TCZþMTX & TCZþPBO gps, respectively
(P¼NS). ACR20/50/70/90 response rates were 72%/45%/25%/
6%(TCZþMTX)& 71%/41%/26%/5%(TCZþPBO)(all P¼NS).
Progression of structural damage was low (Table 1). BL characteristics
did not affect outcomes. HAQ-DI & RAQoL improved significantly from
BL, with no differences between gps (Table 1). Rates per 100 pt-yrs of
serious adverse events (SAEs) & serious infections were 21 & 6 for
TCZþMTX & 18 & 6 for TCZþPBO. AE-related discontinuations &
dose modifications occurred in 3.9% & 27.4% of TCZþMTX & 2.9% &
18.5% of TCZþPBO pts, respectively. ALT elevations >60 U/L were
observed in 16% and 6% of TCZþMTX & TCZþPBO pts.
TABLE 1 Radiographic & QoL results at week 24
Genant-modified Sharp Score (GSS), mean (SD) TCZþMTX N¼ 277 TCZþPBO N¼ 276 Between-group
difference (95% CI)
Total GSS
. Baseline 30.4 (31.8) 37.1 (40.5)
. Baseline annualized progression rate 3.71 4.47
. Change from baseline 0.08 (1.88) P¼ 0.3304* 0.22 (1.11) P¼ 0.3304* 0.13 (0.39, 0.13)
JSN Score
. Baseline 14.7 (17.3) 17.7 (21.7)
. Change from baseline 0.08 (1.49) P¼ 0.8235* 0.11 (0.70) P¼ 0.8235* 0.02 (0.22, 0.17)
. Erosion Score Baseline 15.7 (15.4) 19.4 (19.8)
. Change from baseline 0.01 (0.79) P¼ 0.0871* 0.11 (0.63) P¼ 0.0871* 0.11 (0.23, 0.02)
No progression in GSS (patients with changes¼ 0), n (%)
. Total GSS 181 (65.3) 162 (58.7) P¼ 0.0871y
. JSN Score 218 (78.7) 203 (73.6) P¼ 0.1319y
. Erosion Score 190 (68.6) 179 (64.9) P¼ 0.3317y
QoL data Change from baseline, mean (SD)
. HAQ-DI 0.56 (0.67) 0.55 (0.53) P¼ 0.9323z
. RAQoL 5.97 (7.95) 5.19 (7.06) P¼ 0.3080z
*P-values are for between-group differences in adjusted means (change from baseline to week 24) from the analysis of covariance. yP-values are for between-group
differences (two-sided Cochran-Mantel-Haenszel test stratified for region and baseline DAS28). zP-values are for between-group differences (two-sided Wilcoxon rank-sum
test of no difference between the 2 treatment groups in change from baseline).
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Conclusions: TCZþMTX was not clinically superior to TCZ mono-
therapy based on DAS28 remission rates and other efficacy endpoints.
There was near-complete arrest of progression of structural damage
and significant improvement in QoL with both treatments. Safety data
confirm previous findings.
Disclosure statement: All authors have declared no conflicts of
interest.
O17. SECUKINUMAB TREATMENT PROVIDES SUSTAINED
RESPONSE OVER ONE YEAR IN PATIENTS WITH
RHEUMATOID ARTHRITIS
Patrick Durez1, Mark C. Genovese2, Hanno B. Richards3,
Jerzy Supronik4, Eva Dokoupilova5, Jacob A. Aelion6,
Sang-Heon Lee7, Christine E. Codding8, Herbert Kellner9,
Takashi Ikawa10, Sophie Hugot3, Gregory Ligozio11 and
Shephard Mpofu3
1Rheumatology, Universite´ Catholique de Louvain, Louvain, Belgium;
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NZOZ Centrum Medyczne Artur Racewicz, Bialystok, Poland;
5Department of Medicine, Medical Plus, Uherske Hradiste, Czech
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& Internal Medicine, Health Research of Oklahoma, Oklahoma,
United States of America; 9Rheumatology, Centre for Inflammatory
Joint Diseases, Munich, Germany; 10Department of Medicine,
Kobe-Konan Yamate Clinic, Kobe, Japan; 11Integrated Hospital Care,
Novartis Pharmaceuticals Corporation, East Hanover, New Jersey,
United States of America
Background: In a proof-of-concept study, secukinumab showed rapid
and significant improvement of signs and symptoms in rheumatoid
arthritis (RA) patients relative to placebo, We assessed efficacy and
safety of secukinumab in RA patients despite stable methotrexate
(MTX) up to Week (wk) 52.
Methods: Adult RA patients (n¼237) on MTX were randomized
equally to receive monthly s.c injections of secukinumab 25 mg, 75 mg,
150 mg, 300 mg or placebo. After wk16, responders on secukinumab
remained on the same dose whereas doses were escalated in non-
responders at wk20 (except patients initially on 300 mg who remained
on the same dose). All placebo patients were switched to secukinu-
mab 150 mg. Patients were followed up to wk52. Primary endpoint
was the proportion of patients achieving American College of
Rheumatology (ACR) 20 at wk16.
Results: Demographics and baseline characteristics were comparable
across all groups. At wk16 ACR20 responders were higher with
secukinumab 75 mg, 150 mg and 300 mg vs placebo (47%, 47% and
54% vs. 36%) but did not reach statistical significance. Responders on
secukinumab at wk 16 maintained their ACR responses through wk52;
for the 25 mg, 75 mg, 150 mg, 300 mg cohorts ACR20 responses were
67%, 57%, 90% and 71%, respectively. Highest responses in ACR50/
70 responses at wk24 and wk52 were seen in patients who remained
on secukinumab 150 mg for the entire study (wk24: ACR50¼ 50%,
ACR70¼20%; wk52: ACR50¼55%, ACR70¼ 40%). DAS28-CRP
reductions were sustained up to wk52 in responders on secukinumab
150 mg along with improvement in HAQ scores (-0.6¼wk24 vs
0.8¼wk52) and EULAR remission rates (DAS28-CRP 2.6: 30%¼
wk24 vs 40%¼wk52). Non-responders did not gain much additional
efficacy benefit after dose escalation as assessed by ACR20/50/70
and DAS28-CRP. The overall rates of AEs from wk20 - 60 were
comparable to those observed up to wk20 (60-70%) and most AEs
were mild to moderate in severity and did not lead to study
discontinuation. Between wk 20 - 60 the rate of infections was
31.9% with six infections reported as SAEs. A total of 28 SAEs were
reported in 21 patients. In this period, three malignancies and no
deaths were reported.
Conclusions: The primary efficacy endpoint was not achieved in this
study. ACR20 responders at wk16 showed sustained improvement of
efficacy through wk52 with highest efficacy in patients who remained
on 150 mg throughout the study. DAS28-CRP and HAQ scores
improved through week 52 in responders who remained on secuki-
numab 150 mg. There were no safety signals with secukinumab related
to specific organ class and the rate and frequency of AEs remained
stable over time with no unexpected safety findings.
Disclosure statement: P.D. received research grants from Abbott,
Roche, Schering-Plough and Wyeth, and is a member of the speakers
bureaus of Abbott, Centocor, Roche, Schering-Plough, UCB and
Wyeth. M.G. received research grants and consultancy fees from
Novartis. S.H. is an employee of, and holds stock, stock options or
bond holdings in, Novartis. G.L. is an employee of Novartis. S.M. is an
employee of, and holds stock, stock options or bond holdings in,
Novartis. H.R. is an employee of Novartis. All other authors have
declared no conflicts of interest.
O18. WITHDRAWAL OF ADALIMUMAB IN EARLY
RHEUMATOID ARTHRITIS PATIENTS WHO ATTAINED
STABLE LOW DISEASE ACTIVITY WITH ADALIMUMAB PLUS
METHOTREXATE: RESULTS OF A PHASE 4, DOUBLE-BLIND,
PLACEBO-CONTROLLED TRIAL
Arthur Kavanaugh1, Paul Emery2, Roy Fleischmann3,
Ronald Van Vollenhoven4, Karel Pavelka5, Patrick Durez6,
Benoıˆt Gue´rette7, Sourav Santra8, Laura Redden8, Hartmut Kupper9
and Josef S. Smolen10
1Division of Rheumatology, Allergy and Immunology, University of
California, San Diego, La Jolla, California, United States of America;
2Department of Rheumatology, Leeds Teaching Hospital, Leeds,
United Kingdom; 3Department of Rheumatology, University of Texas
Southwestern, Dallas, Texas, United States of America; 4Department
of Rheumatology, The Karolinska Institute, Stockholm, Sweden;
5Department of Rheumatology, Charles University, Prague, Czech
Republic; 6Department of Rheumatology, Universite´ Catholique de
Louvain, Louvain, Belgium; 7GPRD, Abbott, Rungis, France; 8GPRD,
Abbott, Abbott Park, Illinois, United States of America; 9GPRD,
Abbott, Ludwigshafen, Germany; 10Department of Rheumatology,
Medical University of Vienna and Hietzing Hospital, Vienna, Austria
Background: Treatment with adalimumab (ADA)þmethotrexate
(MTX) has been shown to be effective in inducing low disease activity
(LDA) or remission in early, active, MTX-naı¨ve RA pts. This study
assessed outcomes after 52 weeks of double-blind withdrawal or
continuation of ADA in early RA pts who achieved a stable LDA target
(DAS28 <3.2 at wks 22 & 26) with initial ADAþMTX.
Methods: MTX-naı¨ve pts 18 years old with RA< 1 year and
DAS28(CRP)>3.2, ESR28 mm/hr or CRP1.5 mg/dL, and either
>1 erosion, RFþ, or anti-CCPþ were randomized to ADAþMTX
(n¼ 515) or PBOþMTX (n¼517) for 26 wks (Period 1, P1). Pts who
achieved the stable LDA target were re-randomized to continue
ADAþMTX [ADAþMTX(R)!ADAþMTX] or have ADA withdrawn
[ADAþMTX(R)!PBOþMTX] for an additional 52 wks (P2). Clinical,
radiographic, and functional outcomes were evaluated. Logistic
regression was used to determine baseline (BL) predictors of stable
composite outcomes (DAS28<2.6 or SDAI 3.3, and HAQ< 0.5, and
mTSS0.5 from wks 52-78) in ADAþMTX(R)!PBOþMTX pts. Pts
were monitored for adverse events (AEs).
Results: Of 466 ADAþMTX pts completing P1, 207 (44%) achieved
the stable LDA target and were re-randomized to ADAþMTX(R)
!PBOþMTX (n¼ 102) or ADAþMTX(R)!ADAþMTX (n¼ 105).
Mean BL characteristics were similar for the two groups (RA duration
3.9 mos, DAS28 5.9/5.7, CRP 28.4/23.5 mg/L, TJC68 25.5/23.3,
SJC66 16.4/15.4, HAQ 1.62/1.39, and mTSS 12.2/10.8). Outcomes
at wk 78 were generally comparable, although significantly more
ADAþMTX(R)!ADAþMTX pts achieved higher levels of disease
control, and numerically fewer pts had radiographic progression
(Table). Only lower BL HAQ predicted achieving stable composite
outcomes from wks 52-78 (P< .01) in ADAþMTX(R)!PBOþMTX
pts. AEs [n (%)] in 863 pts with any ADA exposure: SAEs, 106 (12.3);
serious infections, 35 (4.1); malignancies, 11 (1.3) including
TABLE 1. Outcomes at Week 78 (LOCF unless otherwise specified)
Treatment group ACR20/50/70, % DAS28
<3.2, %
DAS28
<2.6, %
SDAI
11, %
SDAI
3.3, %
mTSS
0.5, %*
mean
mTSS*
mean
HAQ
ADAþMTX(R)!PBOþMTX 94/80/65 81 66 84 51 81 0.3 0.35
ADAþMTX(R)!ADAþMTX 95/89/77 91 86 92 62 89 0.1 0.33
P value .72/.11/.05 .04 .001 .07 .1 .06 .69 .66
* Multiple imputation.
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nonmelanoma skin cancer, 4 (0.5); opportunistic infections (excluding
TB), 8 (0.9); confirmed TB, 4 (0.5); deaths, 9 (1.0).
Conclusions: Most MTX-naı¨ve pts with early, active RA who achieved
stable LDA after 26 wks of ADAþMTX treatment maintained good
clinical, radiographic, and functional responses through wk 78 upon
removal of ADA. Lower HAQ at BL predicted stable disease remission,
normal function, and no radiographic progression. More pts who
remained on ADAþMTX achieved higher levels of disease control
compared with pts who had ADA removed, suggesting that certain pts
may benefit from continued ADAþMTX therapy.
Disclosure statement: P.D. is a member of the speakers bureau of
BMS. P.E. is a consultant to Abbott, Merck, Pfizer, Roche and BMS.
R.F. received grant/research support from, and was a consultant to,
Abbott. B.G. is an employee of, and possible stock/option holder in,
Abbott. A.K. is a consultant to Abbott. H.K. is an employee of, and
possible stock/option holder in, Abbott. K.P. is a member of the
speakers bureaus of Abbott, Roche, MSD and BMS. L.R. is an
employee of, and possible stock/option holder in, Abbott. S.S. is an
employee of, and possible stock/option holder in, Abbott. J.S.
received grant/research support, and is a consultant to, Abbott. R.V.
received research support from, and is a consultant to, Abbott, Glaxo
SmithKline, Merck, Pfizer, Roche and UCB. All other authors have
declared no conflicts of interest.
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O19. THE IMPACT OF PAIN ON
SUCCESSFUL AGEING
Ross Wilkie1, Abdelouahid Tajar2 and
John McBeth1
1Keele University, Keele, United Kingdom; 2Centre for Statistics
in Medicine, Oxford University, Oxford, United Kingdom
Background: With population ageing there is a growing drive to
promote a healthier old age and ways to age successfully. Successful
ageing is a multi-faceted state, which involves preservation of
biomedical, physical, psychosocial and lay components to enable
cognitive, physical and mental well-being, social participation and
quality of life. Musculoskeletal pain is common in older adults and
is considered as a stressor which impacts on a number of body
functions. This is the first longitudinal study to investigate the
relationship between musculoskeletal pain and successful ageing in
the general population.
Methods: Population-based prospective cohort study of adults aged
50 years and over, the North Staffordshire Osteoarthritis project was
conducted. Subjects were those who had completed questionnaires at
baseline, 3 and 6-year follow-ups. Based on their reports of pain,
subjects (n¼2949) were classified into those reporting no, regional
and widespread pain (ACR criteria). Using published methodology a
33-item successful ageing index (SA) was constructed by summing the
number of deficits across biological, psychological and functional
domains. SA scores were calculated for each subject at baseline,
3 and 6 years by dividing the number of deficits by the total number of
potential deficits and was expressed as a score from 0 to 100. Linear
regression models were used to test the association between SA in
each time point and pain status at baseline. Mixed modelling was used
to explore the longitudinal trends in SA across six years; pain was
included as a time varying variable to examine the impact of change in
pain status on SA. These associations were then adjusted for potential
confounders: gender, education and baseline social networks, use of
analgesia and diagnoses of chronic musculoskeletal conditions
(osteoarthritis and inflammatory arthropathies).
Results: Median age of subjects was 61 (IQR: 55 to 67). 54% were
female. At baseline 834 (28.7%) had no pain, 1296 (44.5%) had
regional pain and 780 (26.8%) had widespread pain. Baseline regional
and widespread pain were associated with higher SA scores at all
three time points (p< 0.05); those with widespread pain had the
highest scores. Increasing pain was associated with increasing SA
scores over time; an increase from none to regional and regional to
widespread pain resulted in a 19% and 17% increase in SA scores
respectively. An increase from none to widespread lead to a 40%
increase in SA score. Adjustment for diagnosed musculoskeletal
conditions and analgesic use had little effect on the impact of pain on
increasing SA scores.
Conclusions: The results indicate that pain has a significant adverse
affect on successful ageing. At baseline, individuals with regional and
widespread pain had accumulated significantly more signs of less
successful ageing than those with no pain. The longitudinal results
indicate that increasing pain significantly accelerates the rate of less
successful ageing, independent of diagnoses and analgesia.
Disclosure statement: All authors have declared no conflicts of
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O20. FOREFOOT BURSAE ARE A
PROGNOSTIC INDICATOR OF DISABLING
FOOT COMPLICATIONS IN PATIENTS
WITH RHEUMATOID ARTHRITIS:
RESULTS OF A PROSPECTIVE
THREE-YEAR STUDY
Lindsey S. Hooper1,2, Catherine J. Bowen1,2, Lucy Gates1,2,
David Culliford1, Christopher J. Edwards1,2 and Nigel K. Arden2,3
1Faculty of Health Sciences, University of Southampton,
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University Hospitals NHS Trust, Southampton, United Kingdom;
3Nuffield Department of Orthopaedics, Rheumatology and
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Background: Foot complications represent a significant burden to
patients with RA in terms of pain, but also because of the disabling
nature of impaired mobility. There is limited evidence to suggest which
patients may go on to experience the greatest burden of disability and
what factors may be clinically relevant treatment targets in the
prevention and management of such cases. Thus, the study aim was
to determine the natural history of foot related disability in patients with
RA. A secondary aim was to identify potential explanatory variables
either associated with or predictive of disabling foot complications
in patients with RA.
Methods: Patients with RA were consecutively, prospectively
recruited from a Southampton rheumatology outpatient clinic. Data
collection was completed at baseline (N¼149), one-year (n¼120) and
three-year follow-up (n¼60). Patient-reported disabling foot compli-
cations were evaluated using the two subscales of the Foot
Impairment Score; foot impairment/footwear restriction (FISIF) &
activity limitation/participation restriction (FISAP), and a visual analo-
gue scale of overall wellbeing. Explanatory variables investigated
included ultrasound detectable forefoot pathology and markers of
disease activity. The main statistical methods used were multiple linear
regression and tests of linear association (Pearson’s Correlation
coefficient; PCC).
Results: Overall patient-reported disabling foot complications
were highly prevalent across all time points (Table 1). Changes in
foot impairment and activity limitation were significantly associated
with fluctuations in disease activity (FISIF: DAS28-ESR PCC¼0.455,
p¼0.000; ESR PCC¼0.356, p¼0.008, FISAP: DAS28-ESR
PCC¼0.433, p¼0.001; ESR PCC¼0.439, p¼0.001), and
approaching a significant association with changes in forefoot
bursae (FISIF: PCC¼0.255, p¼0.063; FISAP: PCC¼0.255,
p¼0.063). Disease duration and forefoot bursae prevalence were
identified as significant prognostic indicators of foot impairment
(p¼0.009, p¼0.012 respectively), explaining 16% of score variability
in the final regression model (R2¼0.16). Disease duration, forefoot
bursae and erosion prevalence were identified as significant prog-
nostic indicators of activity limitation (p¼0.006, p¼0.019, p¼0.002,
respectively), explaining 35% of score variability in the final regression
model (R2¼ 0.35). No factors were identified as significant predictors
of overall wellbeing.
Conclusions: Forefoot bursae are both predictive of and associated
with patient reported disabling foot complications longitudinally, and
may represent a relevant treatment target and prognostic indicator of
long term foot health.
TABLE 1. Longitudinal changes in patient-reported disabling foot complications
BASELINE
Mean, (SD),
Range
YEAR ONE
Mean,(SD),
Range
YEAR THREE
Mean,(SD),
Range
FISIF 10.7 (4.8), 0-20 10.4 (5.1), 0-20 10.4 (5.1), 0-20
FISAP 16.9 (10.3), 0-29 17.3 (9.9), 0-30 17.4 (9.8), 0-30
Disclosure statement: All authors have declared no conflicts of
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O21. THE CONTINUING PROFESSIONAL
DEVELOPMENT FOR HEALTH
PROFESSIONALS WORKING WITHIN
MUSCULOSKELETAL SERVICES: A
NATIONAL UK SURVEY
Jo Adams1, Sarah Ryan2, Hannah Haywood1 and Helen Pain1
1Faculty of Health Sciences, University of Southampton,
Southampton, United Kingdom; 2Staffordshire Rheumatology
Centre, Haywood Hospital, Stoke-on-Trent, United Kingdom
Background: Musculoskeletal health care professionals have expres-
sed concern at the increased difficulties in undertaking continuing
professional development (CPD). CPD includes ‘a wide range of
learning activities through which professionals maintain and develop
throughout their career to ensure that they retain their capacity to
practise safely, effectively and legally within their evolving scope
of practice’. It is conducted to ‘provide the best possible care
for patients’ and can include formal or informal activities. CPD is a
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requirement in many countries for nurses and AHPs, although
recommendations for the time spent on CPD varies, from no specific
time requirements for UK AHPs to 35 hours over three years for UK
Nurses.
Methods: This electronic survey explored the current UK status of
CPD, for nurses and AHPs working in musculoskeletal services. It
formed the second phase of a two part research project funded by
Arthritis Research UK. The first phase used three focus groups and
two telephone conference calls to explore patients, clinicians and
managers experiences of CPD within MSK services. These findings
informed the content and development of this electronic questionnaire
survey. The survey was designed using Question Mark Perception,
administered from the University of Southampton and distributed via
professional bodies and BHPR. Results were collected online and
analysed in SPSS PASW 17 using frequency data and 2 analyses.
Results: 354 responses were analysed, (51.7% physiotherapists; 30.2
% occupational therapists; 9.9% podiatrists; 7.3% nurses; 0.9 %
other). 63.8% of responders worked exclusively in the NHS. 81%
worked in England, 14% in Scotland; 4% in Wales and 2% in Northern
Ireland. 84% of respondents had more than five years’ experience
working with patients who have musculoskeletal conditions.
The most frequent reported reasons for undertaking CPD was to
improve patient care (56%) maintenance of clinical skills (37%) and to
stay up to date (28%). The majority of respondents reported that their
organization was supportive of CPD activities and in applying new
knowledge to practice (86%) however, the most frequently reported
barriers to CPD included lack of funding (78%) and within this group
24% reported no available CPD funding. 68% reported having too
many other tasks including meeting productivity targets and 42%
reported that they could only ‘‘sometimes or never’’ secure CPD study
leave. There were no statistically significant differences in seniority
level nor employment sector in accessing CPD opportunities.
Conclusions: The results indicate that despite the organizational
support for CPD respondents faced substantial challenges accessing
CPD when under pressure to achieve productivity targets, with little
assistance in terms of funding. This discrepancy may indicate that
greater support is required for musculoskeletal nurses’ and AHPs’
CPD needs.
Disclosure statement: All authors have declared no conflicts of
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O22. DEBRIDEMENT OF PAINFUL
FOREFOOT PLANTAR CALLOSITIES IN
RHEUMATOID ARTHRITIS: THE CARROT
RANDOMIZED CONTROLLED TRIAL
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1Division of Musculoskeletal Disease, University of Leeds, Leeds,
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Background: Foot pain is common in rheumatoid arthritis (RA).
Symptoms often occur, due to hard callus arising as a result of
increased pressure over the plantar metatarsal head. Sharp scalpel
debridement of painful plantar callosities is a standard treatment to
relieve discomfort but it carries risks of haemorrhage, ulceration and
introduction of infection. Furthermore, debridement is rarely the sole
course of treatment; functional orthotic therapy and footwear advice/
provision may also be used. Recently, the short-term benefits of callus
reduction for people with RA were called into question.
Methods: 65 patients with RA and presenting with painful forefoot
plantar callosities for the first time were randomized to receive one of
two treatment protocols. The treatment arm comprised regular
debridement of painful forefoot plantar callosities in conjunction with
mechanical interventions (e.g. orthoses, footwear) while the control
arm comprised mechanical interventions alone. The primary outcome
was a reduction in pain on a 100 mm visual analogue scale. Secondary
outcomes included health status (Leeds Foot Impact Scale, a disease-
specific scale for measuring the impact of foot disease in 2 domains:
impairment/footwear (LFISIF) and activity/participation (LFISAP)),
ambulatory function (velocity measured by GAITRite) and complication
rates (ulceration, infection). Patients were followed up for 18 months.
Results: The mean baseline and 18 month follow-up pain scores were
40.8 and 22.3, respectively, for the treatment group and 53.4 and 34.0,
respectively, for the control group. There was no difference between
groups in the primary outcome of pain, allowing for differences in
baseline scores (F¼1.2, p¼ns). Mean baseline and follow-up
GAITRite velocity scores were 90.1 and 89.8 cm/sec for the treatment
group and 85.7 and 88.5 cm/sec for the control group. In the treatment
group, mean baseline LFISIF score was 12.2 and follow-up was 11.3,
mean baseline LFISAP, was 15.3 and follow-up was 15.7. In the control
group, mean baseline LFISIF score was 14.1 and follow-up was 13.2,
mean baseline LFISAP, was 18.0 and follow-up was 16.1. Secondary
outcomes of health status and ambulatory function also showed no
differences between groups. Complication rates were infrequent in
both groups.
Conclusions: Sharp scapel debridement of painful forefoot plantar
callosities in conjunction with mechanical interventions in RA reduced
pain, but the effect was no different from the use of mechanical
interventions alone. The long-term outcomes were consistent with
previous study findings and further question the efficacy of sharp
scapel debridement of painful forefoot plantar callosities in people
with RA.
Disclosure statement: All authors have declared no conflicts of
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Background: Psychological well-being in rheumatoid arthritis is
known to be reduced compared to the general population. The aim
of this study is to examine longitudinal changes in psychological well-
being, normed against the general population, in a large sample of
patients with recent onset RA. Factors related to psychological well-
being at presentation and changes in psychological well-being over
5 years are assessed.
Methods: Data are from the Early Rheumatoid Arthritis Network
(ERAN), a prospective observational cohort recruiting DMARD naı¨ve
patients at presentation from 21 centres in the UK and Ireland. In total,
1235 patients were recruited between 2002 and September 2011.
Patients were re-assessed after 3-6 months, 12 months and then
yearly. Psychological well-being was assessed using the SF36 Mental
Health scale (SF36-MH). Scores on the SF36-MH scales were normed
against the UK general population (mean¼50, SD¼10). Mixed effects
models, incorporating random effects for the baseline level of distress
and linear change, were used to model changes in SF36-MH scores
over the first 5 years of follow-up.
Results: Mean age at onset was 57.1 years and 68% were female.
At presentation to the rheumatologist the mean normed SF36-MH
scores was 46.6 (SD¼11.1). Indicating psychological well-being
to be significantly reduced compared to the general population
(t(955)¼9.27, Cohen’s disease¼.33, p< .001). Younger age
(b¼ .09, p< .001), higher baseline CRP (b¼ .89, p¼ .009), worse
baseline functional disability (HAQ; 2.10, p< .001), and worse
baseline SF36 Vitality score (b¼ .45, p< .001) were all significantly
related to worse baseline SF36-MH score in multivariate analysis. On
average, psychological well-being improved by .50 units per year
(z¼ 3.90, p< .001). By 3 years SF36-MH scores were not significantly
reduced compared to the general population (mean¼49.0,
t(415)¼1.70, Cohen’s disease¼.10, p¼ .091). Significant hetero-
geneity was observed in the rate of change across individuals
(z¼ 2.49, p¼ .013). Improvements in psychological well-being were
attenuated by higher baseline BMI (b¼.04, p¼ .046) and increased
age (b¼.02, p¼ .022). Greater improvements in psychological well-
being were seen in individuals with low baseline SF36 Vitality scores
(b¼.05, p¼ .001), providing some indication of regression to the
mean.
Conclusions: Psychological well-being in early RA, prior to the use of
disease-modifying therapy, is reduced compared to the general
population. Over time psychological well-being normalizes, taking
longer in those with high BMI and increased age.
Disclosure statement: All authors have declared no conflicts of
interest.
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O24. HEALTH PROFESSIONALS’
PERCEPTIONS OF THE EFFECTS OF
EXERCISE ON JOINT HEALTH IN
RHEUMATOID ARTHRITIS PATIENTS II:
A FOLLOW-UP FOCUS GROUP STUDY
Serena Halls1, Rebecca-Jane Law1, Jeremy Jones1,2,
David Markland1, Peter Maddison1 and Jeanette Thom1
1School of Sport, Health and Exercise Sciences, Bangor University,
Bangor, United Kingdom; 2Rheumatology, Betsi Cadwaladr
University Health Board, Bangor, United Kingdom
Background: Exercise is important in the management of RA. Our
research has indicated that RA patients perceive health professionals
(HPs) lack certainty and clarity about exercise in RA management and
its relationship to joint damage (Law et al., 2010). Furthermore, our
questionnaire study of rheumatology HPs suggested that perceptions
of HPs and patients are not congruent (Halls et al., 2011). We therefore
set out to further explore HPs’ perceptions regarding the effects of
exercise on joint health in RA patients’ using focus groups.
Methods: Four moderated focus groups were conducted with multi-
disciplinary teams (MDTs) of rheumatology HPs (n¼24; 19 females, 5
males; 5 rheumatologists, 8 nurses, 5 physiotherapists, 4 occupational
therapists, 2 other HPs; age: 30 - 60 years; duration working with RA: 3
- 32 years) from across the North-West United Kingdom. The main
questions addressed included: (i) What are your thoughts about
exercise and joint health in your RA patients? (ii) What do you tell your
RA patients about exercise? and (iii) Why do the perceptions of
patients and HPs differ? Focus group recordings were transcribed
verbatim and transcripts were analysed using framework analysis.
Discussion with three associated researchers consolidated validation
at different stages of analysis.
Results: Focus group analysis identified twenty one constructs and
five themes as factors relating to HPs’ perceptions of exercise and
joint health in their RA patients. The five emergent themes were:
‘Exercise is beneficial’, ‘Concerns about damage to joints’, ‘Patients
have barriers to exercise’, ‘HP knowledge differs’ and ‘Patients may
think service delivery is vague’.
Conclusions: HPs articulated acute awareness of the benefits and
importance of exercise for RA patients. Concerns regarding exercise,
particularly weight-bearing exercise, were expressed explicitly, as well
as indirectly, which could lead to confusion for RA patients. The
perceived lack of a solid evidence base was highlighted as a reason for
these concerns. Moreover, the complexity of RA treatment and
management was felt to negatively impact the likelihood of exercise
prescription. When managing RA, HPs provide individualized care and
promote self-management. These issues may explain why patients
perceive their MDTs lack certainty and clarity about exercise in RA
management and its relationship to joint damage. Further research is
warranted to address the uncertainties of HPs regarding exercise and
joint health.
Disclosure statement: All authors have declared no conflicts of
interest.
ORAL ABSTRACT 5: CONNECTIVE
TISSUE DISEASES
O25. VARIABILITY IN THE PHENOTYPE OF METABOLIC
SYNDROME OVER TIME IN A MULTICENTRE
INTERNATIONAL INCEPTION COHORT OF PATIENTS
WITH SLE
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Background: The metabolic syndrome (MetS) is a clustering of
metabolic abnormalities associated with an increased risk of devel-
oping diabetes and atherosclerosis. MetS may also contribute to the
increased cardiovascular risk seen in SLE. We examined the
prevalence and phenotype of MetS over the first 2 years of follow-up
in a multicentre international inception cohort of patients with SLE.
Methods: The Systemic Lupus International Collaborating Clinics
Registry for Atherosclerosis (SLICC-RAS) inception cohort enrolled
recently diagnosed (<15 months) SLE patients from 30 centres across
11 countries since 2000. Baseline and annual assessments record
clinical, laboratory and therapeutic data according to a standardized
protocol. MetS was defined according to the 2009 Consensus
Statement from the International Diabetes Federation which requires
any 3 of the following 5 criteria to be met: elevated race-specific waist
circumference (MetS WC); elevated triglycerides or on specific therapy
(MetS TG); reduced HDL-cholesterol or on specific therapy (MetS
HDL); elevated blood pressure or on specific therapy (MetS BP);
elevated fasting glucose or diabetes mellitus (MetS Glucose).
Results: To date 1686 patients have been recruited of whom 1506
(89.3%) were female and the mean (SD) age at enrolment was 35.2
(13.4) years old. 45.1% of patients were Caucasian, 16.1% were of
African backgrounds and 15.2% were Hispanic. Mean (SD) predniso-
lone dose was 24.1 (16.8) mg at enrolment, 24.4 (19.8) mg at year 1
and 16.2 (15.5) mg at year 2. Of the 1494 (86.6%) patients with
sufficient data to determine their MetS status at enrolment 245 (16%)
had MetS, falling to 193/1065 (12.6%) at year 1 and 207/894 (13.5%) at
year 2. Of the 720 patients with complete MetS data over the first
2 years, 526 (73%) never developed MetS, 84 (12.1%) had MetS on at
least 2 occasions and 31 (4.4%) had MetS at every visit. Table 1 shows
the prevalence of each MetS component over time in those with MetS
data. Whilst the prevalence of elevated waist circumference and blood
pressure remains stable, the prevalence of both elevated glucose and
triglycerides fell over time.
Conclusions: MetS was common in this cohort of young, predomi-
nantly female, patients with recently diagnosed SLE. Overall, 27% had
MetS on at least 1 occasion during the first 2 years of follow-up.
Certain components of MetS vary over time in SLE patients and may
be more responsive to changes in inflammatory disease burden and
exposure to therapy.
TABLE 1. MetS phenotype over time
Enrolment (%)
Total n¼ 1494
Year 1 (%)
Total n¼ 1065
Year 2 (%)
Total n¼894
MetS IDF 2009 16 12.6 13.5
MetS WC 48.4 50.8 49.3
MetS BP 46.0 48.5 50.6
MetS TG 46.1 36.8 39.2
MetS HDL 59.1 54.6 55.3
MetS Glucose 20.2 14.1 13.4
Disclosure statement: All authors have declared no conflicts of
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O26. NITRATED NUCLEOSOME LEVELS IN PATIENTS WITH
SYSTEMIC LUPUS ERYTHEMATOSUS: ASSOCIATIONS WITH
ETHNICITY, AUTOANTIBODY STATUS AND ETHNICITY
Sara C. Croca1, Charis Pericleous1, Harry Yong1, David Isenberg1,
Ian Giles1, Anisur Rahman1 and Yiannis Ioannou1
1Rheumatology, University College London, London, United
Kingdom
Background: Many different autoantibodies have been described in
patients with SLE and serological assays have concentrated mainly on
measuring autoantibody levels. Measuring levels of modified autoanti-
gens may also be valuable. Nucleosomes from apoptotic debris are
known to play a key role in pathogenesis of SLE, especially lupus
nephritis. Nitration of histones within nucleosomes may be enhanced
in patients with SLE by the presence of increased serum levels of
reactive nitrogen species characteristic of inflammatory states. We
developed a novel assay for measuring serum nitrated nucleosome
(NN) levels. Here we report on results of this assay in patients with SLE
and associations with ethnicity, autoantibody profile and measures of
disease activity in patients with SLE.
Methods: Multiple stored serum samples (mean 8 per patient) from a
cohort of 49 patients with SLE were tested. The samples had been
obtained over a mean (SD) follow-up period of 89 (46) months. NN
levels were measured using a novel capture ELISA: serum added to a
streptavidin plate pre-coated with a biotinylated anti-nitrotyrosine
antibody followed by detection with a rabbit anti-histone-3 antibody
and then an anti-rabbit IgG HRP conjugated antibody. OD values were
converted to standard absorbance units (AU) by comparison to a
positive control sample loaded on every plate. The mean absorbance
value for each of the patients was calculated. Univariate analysis was
used to investigate association between these levels and age, gender,
ethnicity, disease duration, autoantibody status and disease activity.
For all samples where data were available, we obtained anti-dsDNA
and complement C3 levels and disease activity from a matching date
and from the previous 3 assessments if these had occurred in the
preceding 12 months. Using the British Isles Lupus Assessment Group
(BILAG) index, we categorized the samples by disease activity as
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follows. Current activity (on the date of the sample) was defined as
high if global BILAG score was 5 and low if it was <5). Disease
activity over the most recent 4 assessments was characterized as
persistently low activity (all systems BILAG C, D or E) or persistently
moderate-high activity (A or 1 B in any BILAG system on at least 2/4
occasions). 90% of all samples fell into one of those two categories
and the rest were excluded. Anti-dsDNA was defined as high or normal
based on a cut-off of 50 IU/ml. C3 was defined as low or normal based
on a cut-off of 0.9 g/l.
Results: The assay yielded reproducible results with an intra and
inter-plate coefficient of variation of <10%. The mean age of the
patients was 36 years (SD 13) and 81% were female. 23 were
Caucasian, 18 Afro-Caribbean (A-C) and 8 other ethnicities. 17
patients had no NN at any time-point. In the other 34 patients, NN
levels varied over time (mean 32.4 AU; SD 62.2; min 0; max 270.4).
Age, gender and disease duration were not associated with NN level.
A-C patients had significantly higher NN than other ethnic groups
(p¼0.03). Anti-Sm positivity was strongly associated with higher NN
levels. Mean NN was 103.5 AU in anti-Sm positive and 7.75 AU in anti-
Sm negative patients (p<0.0001). The apparent effect of ethnicity may
be mediated via anti-Sm positivity since A-C patients were significantly
more likely than other ethnic groups to be anti-Sm positive (p¼ 0.04)
and within the A-C group, anti-Sm positive patients had significantly
higher NN levels than anti-Sm negative patients (p¼0.0004). There
was no relationship between NN levels and positivity for anti-La, anti-
Ro, anti-RNP or antiphospholipid antibodies.
As shown in table 1, higher NN levels were significantly associated
with current and persistently high activity, low C3 and high anti-
dsDNA. In addition, we categorized the samples in terms of activity in
individual systems. The highest mean NN levels were seen in patients
with neuropsychiatric flares (n¼ 18, NN¼54.9) and general flares
(n¼ 31, NN¼ 50.3) whereas the lowest were seen in those with
mucocutaneous (n¼ 41, NN¼ 26.2) and cardiovascular (n¼13,
NN¼ 23.2) flares.
Conclusion: NN were found in the serum of 65% of patients with SLE.
Anti-Sm positivity and Afro-Caribbean ethnicity were associated with
significantly higher NN levels. High NN levels were also associated
with high disease activity, high anti-dsDNA and low complement. In
addition, flares in different organ systems may be associated with
different levels of NN.
TABLE 1.
Number of
samples (n)
Mean (SD)
NN level
p-value
(high vs. low)
Persistently moderate-high activity 188 40.50 (51.7) 0.038
Persistently low activity 154 24.8 (72.3)
BILAG< 5 204 25.6 (57.3) 0.045
BILAG 5 171 37.9 (69.3)
Anti-dsDNA
High (>50 IU/ml) 171 29,0 (48.1) 0.035
Normal(50 IU/ml) 177 21.9 (38.6)
C3
Normal (0.9 g/l) 207 20.8 (40.6) <0.0001
Low (<0.9 g/l) 138 31.6 (47.0)
Disclosure statement: All authors have declared no conflicts of
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O27. IS THERE AN ASSOCIATION BETWEEN WARFARIN
AND SURVIVAL IN SSC-PAH PATIENTS TREATED WITH
FIRST-LINE BOSENTAN MONOTHERAPY?
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NHS Trust and UCL Medical School, London, United Kingdom
Background: Bosentan monotherapy is a commonly used first line
therapy in systemic sclerosis associated pulmonary arterial hyperten-
sion (SSc-PAH) but there is limited data on survival in this rare patient
group. Some case series have suggested a possible survival benefit in
patients with idiopathic pulmonary arterial hypertension who are
treated with warfarin, however little is known about its effect in
patients with SSc-PAH. By studying a well defined patient cohort
treated with the same PH-specific therapy, we hoped to identify
whether warfarin treatment was associated with improved survival.
Methods: A retrospective analysis of consecutive patients with newly
diagnosed SSc-PAH at a large regional centre from 2003-July 2010.
Inclusion criteria were: systemic sclerosis and treatment naı¨ve PAH
(mPAP 25 mmHg, PCWP 15) when starting bosentan monotherapy.
Patients with evidence of significant interstitial lung disease on imaging
(HRCT) or lung function tests (FVC<70%) were excluded. Survival
distributions were measured using Cox-Mantel log rank test. Kaplan-
Meier survival estimates were used to investigate the influence of
variables on survival.
Results: 125 patients were identified. The mean age was 63 (range
23-85) and 88% were female (ratio F:M 7.3:1). Disease subtype was
LcSSc in 116 patients (93%) and DcSSc in 9 patients (7%). Mean
haemodynamic values at initial right heart catheterization were mPAP
40 mmHg and PVR 580 dyns.s.cm-5.
Univariate cox regression analysis showed the following factors
were not associated with survival: gender (p¼0.377), age (p¼0.086),
disease type (p¼0.138), baseline NTproBNP (p¼0.527), six-minute-
walking distance (p¼0.114), mPAP (p¼0.273), PVR (p¼0.538),
immunosuppressant therapy (p¼0.473) and WHO functional class
(p¼0.081). Warfarin treatment was the only factor found to have a
significant association with better survival (HR 0.43 p¼ 0.009 95%CI
0.23-0.81).
On multivariate analysis after adjustment for age, disease subtype,
gender and WHO functional class warfarin remained the only
significant prognostic factor (HR 0.50 p¼0.048 95%CI 0.026-0.99).
Kaplan-Meier survival estimates showed that warfarin was associated
with a improved survival (Log-rank p¼ 0.0068.)
Conclusions: We present a novel finding, that warfarin treatment is
associated with a dramatically improved survival in SSc-PAH patients
treated with first line bosentan monotherapy. The benefits associated
with warfarin may be due to unmeasured confounders, its effect on the
disease or interactions between the drugs. Ideally, a randomized
controlled trial is required to investigate with the association is causal.
Disclosure statement: J.C. has received staff support, consultancy
fees, lecture fees and research grants from Actelion, GSK, Pfizer, and
consultancy fees and lecture fees from Bayer and Ely Lilly. C.D. has
received speaker fees from Pfizer, Actelion and GSK, and consultation
and research grants from Pfizer and Actelion. C.H. has received
education and travel grants from Actelion and. B.S. has received
educational and travel grants from Actelion and GSK, and speaker fees
from Actelion. All other authors have declared no conflicts of interest.
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DISEASE IN PATIENTS WITH SYSTEMIC SCLEROSIS
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Kingdom; 5Centre for Rheumatology, Royal Free Hospital, London,
United Kingdom; 6Department of Radiology, Kings College Hospital,
London, United Kingdom; 7Medicine, National Jewish Health,
Denver, Colorado, United States of America; 8Respiratory Medicine,
University Hospitals Coventry and Warwickshire, Coventry, United
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Background: Positive anti-nuclear autoantibodies (ANAs) occur in
75-95% of Systemic Sclerosis (SSc) patients. The specific SSc
autoantibodies (anti-centromere, anti-topoisomerase-1, anti-RNA
polymerase III, anti-U3RNP, anti-U11/U12 RNP and anti-To/Th) have
been shown to correlate with distinct clinical subsets of patients. Other
SSc related autoantibodies (PmScl, Ku, Ro60, La and U1RNP) can be
found in a variety of other connective tissue diseases and in SSc
patients with overlap features. Despite this vast array of autoantibo-
dies, there remains a group of SSc patients that still appear
autoantibody negative. Here we report a new autoantibody in seven
patients with SSc.
Methods: Serum and clinical data were collected from 379 patients with
SSc investigated for interstitial lung disease and a separate 169
unselected SSc patients. Serum was also available from a control
population consisting of 171 patients with other forms of connective
tissue disease (dermatomyositis, polymyositis, systemic lupus erythe-
matosus and rheumatoid arthritis), 141 patients with idiopathic inter-
stitial lung disease and 88 healthy normal controls. All sera were tested
by routine serological techniques followed by radiolabelled protein
immunoprecipitation (IPP) for those samples negative for the most
common SSc-related autoantibodies, anti-centromere, anti-topoi-
somerase 1 and anti-RNA polymerase III autoantibodies. Patients’
sera that immunoprecipitated a novel 30 kDa band were further
analysed by indirect immunofluorescence and IPP using depleted cell
extracts to establish a common reactivity. A combination of non-
radiolabelled IPP and mass spectrometry (MS) was used to identify the
novel autoantigen and findings were confirmed using both immunode-
pletion and IPP-western blotting using commercial antibodies.
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Results: A novel autoantigen with an estimated molecular weight of
30 kDa was recognized by 7 sera with SSc, 6 of whom had confirmed
interstitial lung disease, and by no controls. The seventh novel
autoantibody-positive patient did not have a chest CT but had a
reduced pulmonary gas transfer. Six of the patients had diffuse
cutaneous involvement and four had overlap features with other
autoimmune diseases (two polymyositis and two RA). None of the
seven sera contained other known autoantibodies. Immunodepletion
experiments indicated that all seven serum samples immunoprecipi-
tated the same autoantigen and MS analysis identified the novel
autoantigen as EIF2 (Eukaryotic Initiation Factor 2). These findings
where confirmed by both immunodepletion and immunoprecipitation
western blotting using commercial anti-EIF2 antibodies.
Conclusions: We report a novel autoantibody (anti-EIF2) found in a
small number of patients with SSc (approximately 1%) that appears to
be specific for SSc / SSc-overlap and closely associated with the
presence of interstitial lung disease. Our findings emphasize the close
association between SSc and the development of disease-specific
autoantibodies.
Disclosure statement: All authors have declared no conflicts of
interest.
O29. OPTICAL COHERENCE TOMOGRAPHY VALIDATION:
A NEW QUANTITATIVE IMAGING BIOMARKER FOR
AFFECTED SKIN IN SCLERODERMA
Giuseppina Abignano1,2, Sibel Aydin1, Conception Castillo-Gallego1,
Daniel Woods3, Adam Meekings3, Dennis McGonagle1, Paul Emery1
and Francesco Del Galdo1
1Section of Musculoskeletal Diseases, Leeds Institute of Molecular
Medicine, Leeds, United Kingdom; 2Rheumatology Unit, Second
University of Naples, Naples, Italy; 3Michelson Diagnostics Ltd,
Orpington, United Kingdom
Background: Skin involvement in systemic sclerosis (SSc) is often
primary outcome in clinical trials but it is still orphan of a quantitative
imaging technique. Optical Coherence Tomography (OCT) is an
emerging imaging technology for clinical examination employing a
low-intensity infra-red laser beam and providing high-contrast 2 mm
deep skin images with a 4 micron resolution. The purpose of this study
was to evaluate face validity of OCT in scleroderma.
Methods: Dorsal aspect of forearms was assessed in this study
employing topical probe ‘‘VivoSight’’ (Michelson Diagnostics) and
optics of Swept-source Fourier-Domain type with a laser wavelength
of 1305þ/- 15 nm. A 4 mm area was scanned with 100 scans each of 4
micron thickness. Clinical skin involvement was determined using the
modified Rodnan skin score (mRSS). The study included 5 forearms
scored as ‘‘3’’, 5 scored as ‘‘0’’ and 5 from healthy controls. Matlab
software was employed to calculate mean density of the scans.
Haematoxylin-Eosin (H&E) staining was performed from forearm skin
biopsy, within 1 cm of OCT scanned region, in two SSc patients.
Results: OCT images collected in healthy volunteers showed,
consistently with published findings, a regular hyper-reflective border
of the skin surface (4 micron) and a homogeneous hypo-reflective
epidermal layer (60 micron). The papillary dermis was consistently
visualized as hyper-reflective area compared to the adjacent epidermis
allowing the visualization of the dermal-epidermal junction (DEJ). Mean
Optical Density (OD) data showed that DEJ was a OD nadir region
between 60 and 70 micron from the surface, the papillary dermis a
high density region (OD range: 0.64-0.72; micron range: 60-100) and
the reticular dermis had a OD ranging from 0.72 and 0.4. In contrast
SSc affected tissues (mRSS¼3) showed no DEJ and no increase in
OD in the papillary dermis which appeared with a range density of
0.61-0.56. Interestingly the OD range of this area was almost normal in
patients with mRSS¼0 (OD¼0.64-0.67). Validation with H&E staining
of 2 SSc patients with mRSS¼3 in the target region, confirmed the
localization of the above mentioned density areas.
Conclusions: This is a proof-of-concept validation of face validity of
OCT as quantitative imaging technique of scleroderma skin. Sensitivity
to change ability of OCT is under evaluation to determine whether the
technique could be used as outcome measure of skin involvement in
SSc.
Disclosure statement: All authors have declared no conflicts of
interest.
O30. THE CLINICAL RELEVANCE OF ANTI-RO52 AND
ANTI-RO60 IN PATIENTS IN THE UNITED KINGDOM PRIMARY
SJO¨GREN’S SYNDROME REGISTRY (UKPSSR)
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Background: Primary Sjo¨gren’s syndrome (pSS) is a multi-system
autoimmune disease. Anti-Ro is the most commonly associated
antibody. This can be differentiated into two subtypes, anti-Ro52
and anti-Ro60, each specific to different antigens. Clinical associations
of the subtypes remain controversial in pSS. The UKPSSR is a large
national cohort and biobank of over 600 clinically well characterized
patients with pSS. All data and samples have been collected
prospectively using a standardized proforma as previously described
[1], providing a unique opportunity to explore whether anti-Ro52 and
anti-Ro60 are associated with distinct clinical manifestations in pSS.
Methods: Serum anti-Ro 52 and anti-Ro60 levels were measured
using a high sensitivity Phadia assay on 314 UKPSSR patients as
part of the interim analysis. Patients were stratified according to the
presence of anti-Ro52 or anti-Ro60 and the relationship between
these antibodies and clinical manifestations of pSS were examined.
The EULAR Sjogren’s syndrome disease activity index (ESSDAI) was
used as the basis for stratification of involvement of different organs.
Differences between groups were tested using Chi-squared and
Mann Whitney U tests for categorical and non-parametrical data
respectively.
Results: Anti-Ro52 was positive in 81% of patients and anti-Ro60 in
82%. 8 (2.5%) patients were positive for anti-Ro-52 but not anti-Ro-60,
10 (3.1%) patients were positive for anti-Ro-60 but not anti-Ro52, and
49 (15.6%) patients were negative for both antibodies. There was
a significant association between anti-Ro52 and disease activity in
the biological (RR¼4.6, 95% CI: 2.3, 9.2; p<0.0001) and articular
(RR¼0.7, 95% CI: 0.5, 0.9; p¼ 0.039) domains, abnormality of
Schirmer’s test (RR¼1.6, 95% CI: 1.3, 2.1; p<0.0001) and salivary
flow (RR¼1.13, 95% CI: 1.0, 1.3; p¼ 0.042). There was a significant
association between anti-Ro60 and disease activity in the biological
(RR¼6.2, 95% CI: 2.7, 14.5; p<0.0001) and cutaneous (RR¼6.9,
95% CI: 1.0, 49.3; p¼0.037) domains and Schirmer’s test (RR¼1.4,
95% CI: 1.1, 1.7; p¼ 0.0001). A negative anti-Ro52 was significantly
associated with fatigue visual analogue scores (p¼ 0.034). Positive
anti-Ro60 was significantly associated an elevated overall ESSDAI
score (p¼0.030). There was no significant association between
antibody status and raynauds, renal, haematological, central nervous
system, peripheral nervous system, muscular, glandular, liver or lymph
node involvement, symptom duration, age or sex.
Conclusions: The percentage of patients positive for both subtypes
was similar in this cohort, in contrast to previous literature which
showed a preponderance of anti-Ro52 in pSS. Anti-Ro-52 and anti-60
were associated with articular and cutaneous manifestations respec-
tively. Positivity of either antibodies was associated with increased
disease activity in the biological domains.
Disclosure statement: All authors have declared no conflicts of
interest.
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O31. AUDIT TO ASSESS GP AWARENESS AND
DOCUMENTATION OF BIOLOGICS AND DMARDS IN
PRIMARY CARE PATIENT RECORDS
Charlotte Goodhead1, Priya Shekar1, Clive Kelly1, Gail Francis1,
Ann-Marie Bailey2, Lynsey Thompson1 and Jennifer Hamilton1
1Rheumatology, Queen Elizabeth Hospital Gateshead, Gateshead,
United Kingdom; 2South of Tyne and Wear Medicines Management,
Sunderland Teaching Primary Care Trust, Sunderland,
United Kingdom
Background: Drugs such as subcutaneous (sc) methotrexate and
biologics used for the management of rheumatoid arthritis are usually
hospital prescribed. A previous audit demonstrated biologic drugs
were only documented in primary care EMIS records in 14/111 (13%)
patients attending GP practices north of Tyne and Wear. It is vital that
GP’s are aware of such medications due to infection risk and drug
interactions. Consequently a method for recording hospital prescribed
medications on EMIS was developed along with a shared care
agreement allowing GP’s to prescribe sc methotrexate to stable self
injecting patients.
Methods: All patients on biologic mono or combination therapy
attending Gateshead Rheumatology service were identified (n¼ 205),
as well as patients receiving sc methotrexate in the community
prescribed by GPs (n¼ 56) and all patients currently attending the
hospital methotrexate clinic or receiving hospital prescribed metho-
trexate via a homecare company (n¼82). All GP practices were given
instructions on registering hospital prescribed drugs on EMIS for
existing patients and at initiation of biologic or sc methotrexate therapy
for all those patients started after the EMIS guideline was launched.
GPs were asked to opt into a shared care agreement for patients
receiving sc methotrexate via a primary care BUPA prescription. Each
GP practice was contacted and a receptionist asked to see whether
the drug was listed on EMIS, or whether there was a note on the
computer.
Results: 343 patients were identified. In total 73/205 (36%) of biologic
drugs were listed on EMIS. Of those on biologic monotherapy 37/84
(44%) had the correct medication recorded on the patient’s EMIS
record. This compares with 35/121 (29%) of those on combination
biologic therapy. 77/121 (64%) of the combination biologic group had
only the DMARD registered, 1/121 (0.8%) had only the TNF registered
and 8/121 (7%) no DMARDs listed at all. With regards to hospital
prescribed sc methotrexate 55/82 (67%) GP practices were aware of
prescription but 8 of those patients didn’t have the drug recorded on
EMIS. For those practices where prescribing had been transferred to
the GP it was initially thought that the drug hadn’t been registered in
10/56. On recontacting the practices it was discovered that the drug
had been prescribed in 8/10 as metoject and in the other 2 cases the
drug had been discontinued between the start of the audit and
contacting the GP.
Conclusions: 100% of patients receiving sc methotrexate via a GP
prescription have the medication correctly recorded on EMIS. This
compares with less than 50% of those on hospital prescribed biologic
drugs and 67% of those on hospital prescribed sc methotrexate.
Although an improvement on the previous audit there is a continued
clinical risk. Further work is underway to streamline communication
between hospital and GP prescribing systems and to further refine the
EMIS protocol for hospital prescribed drugs.
Disclosure statement: All authors have declared no conflicts of
interest.
O32. THE MRC PHYSIODIRECT TRIAL: A PRAGMATIC
RANDOMIZED CONTROLLED TRIAL OF PHYSIODIRECT
TELEPHONE ASSESSMENT AND ADVICE SERVICES VERSUS
USUAL CARE FOR MUSCULOSKELETAL PROBLEMS
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4MSK Outpatients, Bristol Community Health, Bristol, United
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Background: Patients with musculoskeletal problems referred by GPs
for physiotherapy often experience long delays before treatment.
Some physiotherapy services have introduced a treatment pathway
called PhysioDirect, involving initial telephone assessment and advice,
with written self-management and exercise advice sent by post.
Patients are invited for face-to-face treatment only when necessary.
Our hypothesis was that PhysioDirect would be equally clinically
effective compared with usual care, but more cost-effective, with
increased patient satisfaction and shorter waits for treatment.
Methods: Multi-centre pragmatic individually randomized trial com-
paring PhysioDirect versus usual care (patients join a waiting list and
receive face-to-face care). PhysioDirect services were established in
four PCTs. Adults with musculoskeletal problems, either self-referred
for physiotherapy or referred from primary care, were invited to
participate and randomized (by remote web-based allocation) to
PhysioDirect or usual care. Outcome data were collected at baseline, 6
weeks and 6 months after randomization. Outcomes were collected by
patient self-report and from medical records, blind to treatment
allocation. The primary clinical outcome was SF36 PCS at 6 months;
secondary outcomes included MYMOP, EQ5D, patient satisfaction,
waiting times, time lost from work. Incremental cost-effectiveness was
assessed using cost per QALY.
Results: 2256 patients were recruited and randomized (1513
PhysioDirect, 743 Usual Care). 1921 (85%) were followed up at
6 months. PhysioDirect and usual care were equally clinically effective
on our primary outcome (difference in mean PCS 0.01, 95% CI 0.80
to 0.79) and using the MYMOP measure (-0.02, 95% CI 0.16 to 0.11).
Time to first assessment was 7 days for PhysioDirect compared to
34 days for Usual Care. Overall satisfaction appeared to be very
slightly higher amongst those offered usual care (3.8% which equates
to 0.19 points on a 6 point scale) which may not be meaningful. NHS
costs were similar in the two arms (PhysioDirect £196.43 versus usual
care £189.19, difference in means £19.30 (-£37.60 to £76.19)) while
QALYs gained were also similar (difference in means 0.007 (-0.003 to
0.016)). Patients in PhysioDirect had a small but earlier improvement in
health status than those in the Usual Care, achieved at an
insignificantly greater cost. Incremental cost per QALY gained was
£2889.
Conclusions: A system of physiotherapy based on initial telephone
and advice, offering face-to-face care only when necessary is equally
clinically effective and broadly acceptable to patients compared with
usual care. Although mean physiotherapy and total NHS costs were
somewhat greater in PhysioDirect there was a gain in QALY compared
to Usual Care due to more rapid improvement in patient outcomes.
Disclosure statement: All authors have declared no conflicts of
interest.
O33. FREQUENCY OF MUSCULOSKELETAL SYMPTOMS
AND PRESENTING COMPLAINTS IN VIDEO-OBSERVED
PRIMARY CARE CONSULTATIONS WITH PATIENTS
AGED 45 AND OVER
Zoe Paskins1, Tom Sanders1, Peter R. Croft1 and Andy B. Hassell1
1Arthritis Research UK Primary Care Centre, Keele, United Kingdom
Background: Most literature relating to musculoskeletal consultations
in primary care relies on data collected retrospectively by questioning
either GP or patient, or by analysing READ code data. Collecting
data using video recordings of consultations has the advantage of
being more accurate, avoiding recall bias and coding bias, and also
facilitates more in-depth study. This abstract reports early findings
from a study of video recorded primary care consultations, which aims
to explore the patterns of consultation in patients with musculoskeletal
symptoms and to understand more about osteoarthritis (OA)
consultations in particular.
Methods: With ethical approval, 5 GPs in 2 practices in Staffordshire
have agreed and participated to date. In 2 half day surgeries per GP,
patients aged 45 and over, attending routine consultations, were
asked to consent to having their consultation video recorded and
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complete a questionnaire regarding their demographics, symptoms
and agenda for the consultation. The video recorded consultations
were then viewed by ZP and actual symptoms discussed and
diagnosis recorded.
Results: 71.4% of eligible patients agreed to participate. Of those
participating, 42.7% were female and 57.3% male, with a mean age of
69 (range 45-91). Table 1 shows the number of patients that reported
having joint pain, the proportions of these that intended to, and
subsequently did discuss joint pain, along with the diagnosis.
Conclusions: The prevalence of joint pain in patients consulting their
GPs has not been reported previously, and the data presented here,
albeit from a small sample, suggests that 49.3% of these patients
aged 45 and over are experiencing joint pain. Data from local GP
databases suggests that 14% of consultations in this age group relate
to musculoskeletal symptoms, yet the data from this study suggests a
higher proportion (21.3%). Furthermore, this study highlights that a
number of patients intend to discuss joint pain but do not ultimately
raise this concern with the GP (10.6%).
Further aspects of this study which include qualitative analysis of
the consultations and post consultation interviews with participants
will provide a fuller picture of the pattern of consultation.
Disclosure statement: All authors have declared no conflicts of
interest.
O34. DECIDING TO CONSULT THE GENERAL
PRACTITIONER FOR SYMPTOMATIC OSTEOARTHRITIS:
A CHOICE-BASED CONJOINT ANALYSIS STUDY
Domenica E. Coxon1, Martin Frisher2, Kelvin P. Jordan1, Clare Jinks1
and George Peat1
1Arthritis Research UK Primary Care Centre, Keele University, Keele,
United Kingdom; 2Department of Medicines Management, Keele
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Background: Symptomatic osteoarthritis (OA) is a major cause of
disability. However, even among people with persistent, severe pain,
many often do not consult their general practitioner (GP) about it over
several years. Previous studies of the determinants of consultation for
OA have focussed almost exclusively on patient characteristics and
clinical need. Yet, given reports of patients’ negative experiences and
low expectations of healthcare services, their perceptions of what
primary care has to offer will also be important. This study investigated
the relative importance of service-related factors and clinical need
factors in the decision to consult a GP for symptomatic OA.
Methods: The design was a partial-profile choice-based conjoint
analysis study based on a cross-sectional survey using a single postal
self-complete questionnaire. Adults aged 50 years and over with hip,
knee, or hand pain were identified from an existing population cohort
study. Eligible potential participants were sent a postal self-complete
questionnaire containing 10 choice tasks, each presenting two
scenarios based on a combination of three out of six selected
attributes (pain characteristics, pain disruption to everyday life, other
current health problems, assessment/investigations available, treat-
ment options available, and GP attitude). Multinomial logit regression
(main effects) was used to estimate the relative importance patients
placed on each of the attributes. Results represent the aggregate
difference between the maximum and minimum utilities, expressed as
logits, for each attribute level. Latent class analysis was used to
identify subgroups of respondents with similar preferences.
Results: 863 (74%) people responded (55% female) (mean age
70 years, range: 58-93). The most important determinant of the
patient’s decision to consult the GP for joint pain was the extent to
which pain disrupted everyday life (1.10 logits). GP attitude (0.86) was
perceived to be more important than the available treatments (0.45) or
assessment/investigations (0.48). The decision to consult the GP for
joint pain was less influenced by other health problems (0.46) and
episodes of more severe, unpredictable pain (0.16). Subgroups
identified by latent class appeared to be based more on differences
in the strength of preferences overall than to differences in the relative
importance of attributes per se.
Conclusions: Service-related factors are as influential as the most
important need-related determinant of consultation (i.e. disruption).
Believing the GP would regard joint pain as ‘part of the normal ageing
process that one just has to accept’ is a strong disincentive to seeking
help, potentially outweighing other aspects of quality of care. Partial-
profile conjoint methods are acceptable to respondents, well-
completed, and can address attributes that are less accessible in
traditional epidemiological designs.
Disclosure statement: All authors have declared no conflicts of
interest.
O35. ARE RHEUMATOID ARTHRITIS PATIENTS SCREENED
FOR CARDIOVASCULAR DISEASE IN PRIMARY CARE?
Helen L. Monk1, Sara Muller1, Christian Mallen1 and Samantha
L. Hider1
1Arthritis Research UK Primary Care Centre, Keele University, Keele,
United Kingdom
Background: The association between rheumatoid arthritis (RA) and
increased risk of cardiovascular disease (CVD) is well recognized,
reflected in EULAR and BSR guidance recommending cardiovascular
screening in RA. Whether this is translated into routine clinical practice
in primary care is less clear. The aim of this study was to compare
rates of primary care CVD screening amongst RA patients and age,
gender and practice-matched controls to determine if the additional
cardiovascular risk associated with RA is being recognized and
managed appropriately.
Methods: This study was undertaken in two linked regional primary
care databases: Consultations in Primary Care Archive (CiPCA) and
Investigations in Primary Care Archive (IiPCA). All patients in the
database with a diagnostic Read Code for RA between 2000 and 2008
and still registered with the practice in 2009 were identified and
matched to 4 controls. CipCA and IiPCA were searched for records of
blood pressure, body weight, smoking status, glucose and cholesterol
monitoring during 2009 in both cases and controls.
Results: 401 RA cases were identified and matched to 4 controls.
Overall, the mean age was 58.7 years and 66% were female. No
difference in screening between cases and controls was identified for
blood pressure, body weight, cholesterol or glucose level. Increased
screening for smoking status was apparent in RA patients (62% versus
67%) (95%CI 0.0%, 10.0%). The rate of screening for each risk factor
was similar in males and females, but those aged over 65 years were
more likely to be screened for any and for all risk factors (p<0.0001).
352 (88%) RA patients had screening for at least 1 CVD risk factor
compared to 985 (82%) controls (difference: 5.8% (95%CI 1.4%,
9.2%). The proportion having a comprehensive CVD screen (all 5 risk
factors) was low (cases 25% versus controls 26%) and similar in cases
and controls (p¼ 0.648).
Conclusions: Despite the well-known association between rheuma-
toid arthritis and cardiovascular disease such knowledge is not being
translated into additional screening for people with rheumatoid
arthritis. More emphasis needs to be placed on ensuring those with
rheumatoid arthritis are actively screened for cardiovascular disease in
primary care.
TABLE 1.
Questionnaire results Viewed consultation
n (%) Actually discussed
joint pain, n (%)
Diagnosis Frequency
Total number of patients that reported having
joint pain within last 7 days
37/75 (49.3) 17/37 (45.9) See below
Of those reporting joint pain, number who
intended to discuss this with GP
23/37 (62.2) 15/23 (65.2) OA None given, pending investigation None
given, advice only Not musculoskeletal
e.g. neurological, flu like illness RA Soft
tissue Gout
2a 3 3 3 2 2a 1
Of those reporting joint pain, number who
did not intend to discuss this with GP
14/37 (37.8) 2/14 (14.3) OA Gout 1 1
Total number of patients that did not
report joint pain within last 7 days
38/75 (50.7) 3/38 (7.9) None given, advice only Soft tissue
Malignancy
1 1 1
Total 20/75 (26.7)
aOne patient had two diagnoses.
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O36. GOUT, ALLOPURINOL AND ERECTILE DYSFUNCTION:
AN EPIDEMIOLOGICAL STUDY IN A PRIMARY CARE
CONSULTATION DATABASE
Edward Roddy1, Sara Muller1, Richard Hayward1 and
Christian Mallen1
1Arthritis Research UK Primary Care Centre, Stoke-on-Trent,
United Kingdom
Background: Erectile dysfunction (ED) is prevalent in the general
population, affecting 2% of men under 40 years rising to 86% of
those aged over 80 years. Risk factors for ED are similar to those for
gout and include diabetes mellitus, vascular disease, hypertension,
obesity and alcohol use, raising the possibility that gout and ED are
associated. Furthermore, impotence is described as a rare side-effect
of allopurinol. However, no published epidemiological studies have
explored possible associations between gout, allopurinol and ED.
The objectives of this cross-sectional epidemiological study were to
examine the association between ED and, firstly, gout and, secondly,
allopurinol, adjusting for confounding co-morbidities and co-
prescriptions.
Methods: Data were taken from a validated database of general
practice records from nine practices in the UK covering 64,747 adults
between 2001 and 2008. Men consulting for gout were identified via
Read codes and each matched with four controls for age, practice and
year of gout consultation. Consultations for ED, ischaemic heart
disease (IHD), hypertension and diabetes mellitus were also identified
via Read codes. Prescription of allopurinol, diuretics, anti-
hypertensives, H2 antagonists and anti-depressants were categorized
according to British National Formulary codes and then identified in
a linked prescription database. Unadjusted odds ratios (OR) were
calculated between gout and ED and then adjusted for the presence
of IHD, hypertension, diabetes mellitus, and prescription of diuretics,
anti-hypertensives, H2 antagonists and anti-depressants, using
logistic regression models. In gout cases only, the association
between allopurinol prescription and ED was examined adjusting for
the same potential confounders.
Results: 1292 men with gout were identified and successfully
matched to four controls. Mean age was 59.9 years. IHD, hyperten-
sion, diabetes mellitus, and prescription of diuretics, anti-hyperten-
sives, and H2 antagonists, but not anti-depressants, were more
prevalent in gout cases than controls. 116 (9.0%) men with gout
consulted with ED compared to 429 (8.3%) of controls (adjusted OR
0.97; 95%CI 0.78, 1.22).
Of those men who consulted with gout, 506 (39%) had received at
least one prescription for allopurinol. Consultation with ED occurred in
65 (12.9%) men who received allopurinol and 51 (6.5%) who were
not prescribed allopurinol (unadjusted OR 2.22; 95%CI 1.50, 3.28).
This association remained significant after adjustment for IHD,
hypertension, diabetes mellitus, and prescription of diuretics, anti-
hypertensives, H2 antagonists and anti-depressants (OR 1.92; 95%CI
1.28, 2.87).
Conclusions: Gout per se is not associated with ED. However,
allopurinol prescription is associated with ED after adjustment for
multiple confounding co-morbidities and co-prescriptions. Prescribers
should be aware of allopurinol as a cause of ED amongst men with
gout.
Disclosure statement: All authors have declared no conflicts of
interest.
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